Lenscrafers #00855 Eyewear Supplier (Equipment, not the service) Location: 2526 S Third St, Jacksonville, Florida 32250 Phone: (904) 247-2374 |
Lenscrafters #00708 Eyewear Supplier (Equipment, not the service) Location: 9041 Southside Blvd, Jacksonville, Florida 32256 Phone: (904) 519-5768 |
Lenscrafters #03209 Eyewear Supplier (Equipment, not the service) Location: 4668 Town Crossing Dr, Jacksonville, Florida 32246 Phone: (904) 641-2738 |
Lenscrafters # 2279 Eyewear Supplier (Equipment, not the service) Location: 10300 Southside Blvd, Jacksonville, Florida 32256 Phone: (904) 363-0878 |
Lenscrafters #02275 Eyewear Supplier (Equipment, not the service) Location: 4495 Roosevelt Blvd, Jacksonville, Florida 32210 Phone: (904) 388-0948 |
News Archive
From the 1st to the 3rd of March 2011, vaccine leaders from developing and developed world will meet at Vaccine World Summit in New Delhi. The event will be hosted by IMAPAC, in partnership with DCVMN (Developing Countries Vaccine Manufacturers Network).
A team of interventional neuroradiologists and neurosurgeons at Johns Hopkins reports wide success with a new procedure to treat pseudotumor cerebri, a rare but potentially blinding condition marked by excessive pressure inside the skull, caused by a dangerous narrowing of a vein located at the base of the brain.
A large, retrospective study of the children of childhood cancer survivors who were treated with radiation therapy and/or some forms of chemotherapy found that the offspring do not have an increased risk for birth defects compared to children of cancer survivors who did not receive such treatments.
Medivation, Inc. and Astellas Pharma Inc. today announced treatment of the first patient in a second Phase 3 clinical trial of the investigational drug MDV3100, which expands the Phase 3 development of the novel, triple-acting oral androgen receptor antagonist into an earlier-stage patient population. Known as PREVAIL, the trial will evaluate MDV3100 in men with advanced prostate cancer who have not yet received chemotherapy. Initiation of the PREVAIL trial triggers a milestone payment to Medivation under its collaboration agreement with Astellas.
› Verified 1 days ago